← Latest news 
Dr Reddy’s shares slide as Goldman downgrades and Citi goes cautious on pipeline risks
Business
Published on 24 April 2026
Analysts cite pipeline worries and generics pricing pressure
Dr Reddy’s shares dropped about 2% after Goldman Sachs downgraded the stock and Citigroup turned cautious. Brokerages pointed to limited growth visibility, pipeline concerns, and valuation risks, alongside generics pricing pressure. Citi also flagged muted near-term opportunities in semaglutide, prompting analysts to warn that downside risks may persist despite earlier optimism.
- Dr Reddy’s shares fell after Goldman downgraded
- Citi warned about limited growth visibility and valuation risks
- Pipeline concerns and generics pricing pressure weighed on outlook
- Muted semaglutide opportunities added to near-term downside risk
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times